Codexis and Matrix Laboratories enter into partnership for development and commercialization of novel process
Codexis announced it has signed an agreement with Matrix Laboratories (Matrix), a leading provider of active pharmaceutical ingredients (APIs) to the global pharmaceutical industry, for the development and commercialization of the API for a high-value pharmaceutical product.
Codexis will employ its proprietary pharmaceutical process re-engineering technology platform to develop a novel synthetic process for the product via a Codexis Thoroughbred(TM) biocatalyst. The process will be transferred to Matrix for scale-up and manufacturing. Under the terms of the collaboration, Codexis will receive research and development funding, milestone payments and a royalty on net sales of the product. Matrix will receive exclusive manufacturing and marketing rights to the novel process. Further financial terms were not disclosed.
Other news from the department business & finance
These products might interest you
Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
